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Abstract
Background: Comprehensive tumour genomic profiling (CGP) offers hope for personalised treatment
for cancer patients when other treatment options have been exhausted. However, receipt of nonactionable or ambiguous results could be an ongoing source of distress. We investigated patterns of
hope, anxiety, depression and CGP-specific anxiety in advanced cancer patients after receiving CGP
results and 2-3 months later.
Methods: Participants were enrolled in a longitudinal psychosocial sub-study, embedded in the
Molecular Screening and Therapeutics Program, and had advanced solid cancers of any histological
type with sufficient and accessible tissue for CGP. At T0 (before receiving CGP results), 1431
participants completed sociodemographic, disease and psychosocial measures. At T1 (1-4 weeks
after receiving CGP results) and T2 (2-3 months post-T1), 374 participants completed psychological
outcome measures. Predictors of outcomes at T2 were identified using multinomial logistic
regression.
Results: Approximately 75% of participants did not experience significant hopelessness or distress at
T1 and T2. Hope decreased by T2, yet general anxiety and CGP-specific anxiety also decreased.
Receiving actionable results did not impact psychological outcomes at T2. At T2, lower hope, and
higher anxiety, depression and CGP-specific anxiety were associated with lower self-efficacy.
Psychological and demographic factors (age, socioeconomic status, language, medical occupation,
urban living, family history of cancer) independently predicted one or more psychological
trajectories. Worse health status and perceived susceptibility to cancer progression predicted hope
and anxiety trajectories.
Conclusion: Further research on interventions to best support patients undergoing CGP with high
anxiety, hopelessness, fear of cancer progression and poorer health is urgently needed.
Keywords: molecular profiling; genomics; genetics; psycho-oncology; resilience
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With greater understanding of the molecular basis of cancer, reduced costs and improved
technology, comprehensive tumour genomic profiling (CGP) is increasingly used to guide
prognostication and personalised treatment for cancer. However, while CGP can identify variants
that guide treatment (clinically actionable) (Mandelker et al., 2017), more commonly CGP will not
identify variants of therapeutic potential. Even if patients receive an actionable result, they may be
unable to access linked treatment. Particularly for patients with advanced cancer with few remaining
treatment options, CGP can be a rollercoaster of raised expectations and dashed hopes (Malone,
Oliva, Sabatini, Stockely, & Siu, 2020).
It is important to understand the potential psychological outcomes of genomic testing, to
prepare patients and guide provision of appropriate counselling services. While research on
psychological outcomes of single gene (Ringwald et al., 2016) and multigene (Hamilton, & Robson,
2019) testing in the germline has been reassuring, it is unclear how this applies to the complex
scenario of CGP. A recent systematic review on psychological outcomes of genomic testing
concluded that research is limited and focused almost exclusively on women with breast cancer
(Yanes, Willis, Meiser, Tucker, & Best, 2018). Most studies evaluated assessment of risk of
recurrence (not tumour markers) to guide treatment choices, and none chose variables based on a
model of illness adjustment. In one study, young adults with high-risk solid tumours, or parents of
children with such tumours, who had received CGP results did not regret undergoing CGP and stated
CGP had not elevated their anxiety or stress levels (Marron et al., 2016). However, as this study did
not measure psychological outcomes directly and was cross-sectional, further longitudinal,
theoretically driven research assessing patient reported outcomes in an adult advanced cancer
population is warranted.
A meta-analysis of BRCA1/2 mutation carriers and non-carriers summarised that women
who were mutation carriers experienced higher emotional distress immediately after receiving
results, which decreased to pre-testing levels with time (Hamilton, Lobel, & Moyer, 2009),
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highlighting the complex interplay between the impact of cancer and receipt of genetic and genomic
tests on one’s emotional state. In our earlier work we found that despite the possibility of genomic
testing increasing psychosocial concerns particularly when receiving unwanted knowledge, the

majority of advanced cancer patients were interested in receiving results, especially if they
were actionable (Best et al., 2020), which is supported by other studies (Hamilton et al.,
2017). Concurrently, we also found that patients had heightened optimism and hope that
the result would be actionable and that a drug would be readily available and successful for
their cancer, despite being informed that the likelihood of receiving an actionable result
following CGP was low (Best et al., 2019). If this expectation was not met, it could increase
emotional distress. However, hope, anxiety, depression, and CGP-related anxiety following
receipt of CGP results have not yet been specifically studied among advanced cancer
patients.
To address this gap in the literature, we applied an adapted version (Baum, Friedman, &
Zakowski, 1997) of the Transactional Model of Stress and Coping (Lazarus, & Folkman, 1984) as a
guide to understanding potential factors influencing psychological adjustment to CGP. According to
this model (Baum et al., 1997), CGP result (actionable or non-actionable, and if actionable, whether
treatment is available) and personal factors (e.g., perceived self-efficacy and coping skills) could
determine how someone responds to these stressors and subsequently this can impact the
psychological outcomes of receiving results (i.e., coping and consequences). Similarly, the
Uncertainty in Illness Model (Mishel, 1990) posits that uncertainty regarding actionability of results
can lead to either opportunities or pitfalls, which determines how the individual copes and adapts.
This is important to consider in conjunction with the Transactional Stress/Coping model because
having a negative attitude to illness uncertainty (inability to determine the meaning or outcome of
illness-related events; Mishel, 1990) can be associated with negative psychological outcomes such as
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excessive anxiety (Rosen, & Knäuper, 2009; Wevers et al., 2012). Furthermore, receiving uncertain or
ambiguous information from genomic tests can increase participants’ disappointment, vulnerability,
anxiety, and hopelessness (Biesecker et al., 2014), which highlights that the actionability of the CGP
result can be an important contributing factor to psychological outcomes.
Therefore, informed by the Transactional Stress/Coping Model (Lazarus, & Folkman, 1984)
and Uncertainty in Illness Model (Mishel, 1990), and the literature (Beran et al., 2008; Rosen &
Knäuper, 2009; Watts et al., 2014; Wevers et al., 2012), we hypothesized that:
1) Psychological outcomes immediately post result-receipt would be maintained at follow-up.
2) Receiving non-actionable results or actionable results with no access to linked treatment
(stressor or danger), would be associated with higher levels of psychological distress at follow-up
(coping or adaptation) than receiving actionable results (positive appraisal or opportunity).
3) Controlling for psychological distress at baseline, participants would have higher levels of
psychological distress at follow-up if they:
a) Are younger, have worse functional performance status and more comorbidities,
whereby these personal variables lead to a positive or negative appraisal (opportunities
or dangers), stress response, coping and adaptation.
b) At baseline feel more susceptible to cancer progression, value CGP more highly, have
less knowledge of CGP, have lower self-efficacy for coping with results and negative
attitudes to uncertainty.

Methods
Participants
This project is a sub-study of the Molecular Screening and Therapeutics (MoST) Program
(Thavaneswaran et al., 2018). MoST enrols adult patients with pathologically confirmed advanced
solid cancers of any histological type, during or after their last line of effective therapy; participants
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have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 and sufficient
accessible tissue for CGP. Participants receive results approximately three months later from their
treating oncologist who discusses CGP results and treatment options with them. If actionable
findings are reported, participants may be enrolled in a related therapeutic trial or other targeted
therapy.
The Psychosocial Issues in Genomics in Oncology (PiGeOn) project is a longitudinal, mixedmethods sub-study of MoST, which aims to examine the psychosocial, behavioural and ethical
impact of CGP (Best et al., 2018). Exclusion criteria are inability to complete assessments.
Participants consent to participate in PiGeOn while giving written consent to participate in MoST.
Both studies were approved by the St Vincent’s Hospital Human Research Ethics Committee
(HREC/16/SVH/23).
Procedure
PiGeOn participants completed measures at baseline (T0, within 2 weeks of consenting to
have CGP, but before receipt of results), shortly after receiving CGP results (T1, 1-4 weeks post
results) and 2-3 months post T1 (T2). Follow-up (T2) was short, to avoid attrition due to illness.
Measures
Demographic and disease variables (only T0)
Demographic variables: gender, age, education, marital status, parental status, language
spoken at home, socio-economic status, urban versus rural status (Accessibility and Remoteness
Index of Australia – ARIA), and medical or science occupation.
Disease variables: family history of cancer (first-degree relative/s), cancer incidence
[common (>12 cases/100,000 population), less common (6-12 cases/100,000 population) or rare (<6
cases/100,000 population)], ECOG performance status, Charlson Comorbidity Index, multiple
primary cancers.
CGP Result
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Results could be: a) non-actionable, b) actionable, with a treatment recommendation
available through a MoST sub-study, c) actionable with no MoST sub-study available, referred back
to oncologist, or d) have a germline origin, which can be returned to family members with
participants’ consent if they are deceased.
Psychosocial predictor variables (only T0)
Knowledge: An eight-item, multiple choice, purpose-developed measure assessed
knowledge of CGP and possible outcomes. Higher scores (summed) indicate greater knowledge.
Perceived susceptibility: Participants indicated perceived likelihood of cancer progression
on a visual analogue scale from 0% (no chance of progression) to 100% (will definitely progress),
adapted from a previous study (Kasparian et al., 2009).
Perceived importance of CGP: A two-item measure adapted from Hay et al. (2012) assessed
perceived importance of genetic information to the participant, using a Likert-type scale. Higher
scores indicate greater importance.
Self-efficacy: Four items adapted from Rosenberg et al. (2013) measured perceived ability to
cope with test results. Higher scores indicate better perceived ability to cope.
Attitudes to uncertainty: The seven-item Attitude towards Uncertainty scale (Braithwaite,
Sutton, & Steggles, 2002) measured on a Likert scale, examines attitude to uncertainty in the context
of medical testing. Higher scores indicate more negative attitudes towards uncertainty.
Psychological outcome variables (T1 & T2)
Hope: The 12-item Herth Hope Index (HHI; Herth, 1992) assessed hope and sense of
meaning with 3 subscales: temporality and future, positive readiness and expectancy, and interconnectedness. Internal reliability has been demonstrated as excellent (Cronbach α = 0.97). Higher
scores indicate greater hope.
Anxiety and depression: The 14-item Hospital Anxiety and Depression Scale (HADS;
Zigmond, & Snaith, 1983) comprised anxiety (HADS-A) and depression (HADS-D) sub-scales. The
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overall HADS has been found to have good reliability among breast cancer patients (Cronbach α =
0.85, Rodgers, Martin, Morse, Kendell, & Verrill, 2005). Higher scores indicate greater anxiety and
depression.
CGP-specific anxiety: The 15-item adapted Impact of Events Scale (IES; Horowitz, Wilner, &
Alvarez, 1979) measured CGP-specific anxiety in two subscales: intrusive thinking and avoidance.
The internal reliability for the intrusion and avoidance subscales has been shown as good (Cronbach
α = 0.88 and 0.84, respectively, Thewes, Meiser, & Hickie, 2001). Higher scores indicate greater CGPrelated anxiety.

Analysis
T-tests (paired sample or independent t-tests, as appropriate), one-way ANOVA and chisquare tests were run to compare means between groups, and correlation analyses were run to
compare associations between variables, respectively (results in Tables 1 and 2 and Supplementary
files). Separate multiple hierarchical linear regression models were built to identify predictors of
each psychological outcome at T2 by controlling for the corresponding T1 psychological outcome
score in Step 1 and inputting all independent variables in Step 2 in the models. By hierarchical linear
model we do not mean mixed models, rather a hierarchy of covariates that are being adjusted
through the two steps of model building.
Next, for each of the four psychological outcomes (i.e., HHI, HADs-A, HADS-D, IES)
participants were divided into ‘low’ and ‘high’ groups at T1 and T2, determined by whether they
were above or below the sub-clinical cut-off score for each measure. Specifically, on the HHI, a cutoff score <35 indicated ‘low’ hope and ≥36 ‘high’ hope (max HHI score =48), on the HADS-A and
HADS-D, a cut-off score ≤7 indicated ‘low’ anxiety or depression, respectively, and > 8 ‘high’ anxiety
or depression, respectively (max HADS-A or HADS-D score = 21), and on the IES, a cut-off score ≤8
indicated ‘low’ CGP-specific anxiety and >9 ‘high’ CGP-specific anxiety (max IES score = 45). These in
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the high groups therefore had high hope and at least mild anxiety, depression and CGP-specific
anxiety, respectively. Four longitudinal trajectories per measure (thus 16 in total) were formed:
‘High-High’, ‘High-Low’, ‘Low-High’, ‘Low-Low’, that were evaluated in this study. . Multinomial
logistic regressions were conducted for each psychological outcome separately using the four T1-T2
trajectory categories. All demographic, disease-related and other psychological variables were
included as independent variables in these analyses.
The power calculation for this study is reported in the protocol paper (Best et al., 2018). To
address the large number of p-values inherent to a multinominal regression, we note a Bonferroni
correction to a .05 cut-off level for 27 variables (α=0.00185). However, we also note this may be
overly conservative as variables are not independent. We therefore present values without
Bonferroni corrections and highlight those additionally below the Bonferroni correction cut-off. We
recommend p-values be treated as a level of evidence for an effect, rather than as ‘significant’ and
‘not significant’. All statistical analyses were conducted using IBM SPSS Statistics Version 26.

Results
In total, 1,537 participants consented to participate in the MoST Program, of whom 1,431
completed the T0 questionnaire (93% response rate), 569 of 1,183 who received results (48%)
completed the T1 questionnaire and 548 of 971 who received results and did not decline T1 (56%)
completed the T2 questionnaire (Figure 1). Of these, 374 of 971 (39%) completed measures on
psychological outcomes at both T1 and T2 and therefore form the sample for this analysis.
The mean age in this sample was 56.4 (SD=13.51) years, with 55.6% female. Two thirds had
an ECOG performance score of 0 (fully active and unrestricted performance). The most common
cancers diagnoses were bone and soft tissue cancer, colon and/or rectum cancer and brain cancer.
The demographic and disease variables for this sample and the total MoST program sample are
presented in Table 1 and the psychosocial variables are presented in Table 2. We compared
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participants in the total MoST sample and participants who completed psychological outcomes;
there were statistically significant differences between the two samples. Participants who
completed the psychological outcome measures were more likely to have received actionable
results [X2 (3) = 76.80, p < .001], less likely to speak a foreign language at home [X2 (1) = 14.23, p <
.001], more likely to have an ECOG score of 0 [X2 (2) = 29.86, p < .001], more likely to have had more
surgeries [X2 (2) = 6.64, p < .036] and had a higher score on self-efficacy at T0 [m=4.4, SD=.63 versus
m=4.3, SD=.69, t(1794)=3.01, p=.003] than the MoST sample. We also compared participants who
completed psychological outcomes both at T1 and T2 and participants who only completed them
either at T1 or T2. Participants who were lost to follow-up at T1 had lower hope [m=37.5 (SD=6.18)
versus m=38.8 (SD=5.52), t(502)=2.40, p=.017], higher general anxiety [m=7.4 (SD=4.68) versus
m=6.6 (SD=4.18), t(557)=-1.98, p=.048] and higher depression [m=6.0 (SD=4.23) versus m=4.5
(SD=3.69), t(557)=-4.01, p=.000] as well as higher general anxiety [m=6.6 (SD=4.35) versus m=5.8
(SD=4.15), t(539)=-2.02, p=.044] and CGP-specific anxiety [m=11.0 (SD=13.69) versus m=8.0
(SD=11.89), t(536)=-2.49, p=.013] at T2 compared to the sample who completed both T1 and T2
psychological outcome measures (Table 2). Thus, our sample represents the better functioning end
of the spectrum within the MoST cohort. One-way ANOVA showed there were no differences in
hope, anxiety, depression and CGP-specific anxiety at T2 among participants who received
actionable or non-actionable results with or without a MoST treatment recommendation (Table S1).
Correlations between hope, anxiety, depression and CGP-specific anxiety at T2 are provided in Table
S2. Results for each psychological outcome are presented below.
Hope
A paired sample t-test showed that hope significantly decreased from T1 to T2 (Table 2). In
multiple regression analyses (Table S3), when controlling for T1 hope, higher T0 self-efficacy and
ECOG, and lower T2 general anxiety and depression predicted higher T2 hope (p<.001, adj. R2=.67).
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Predictors of longitudinal hope. The majority of participants (57.9%) had high hope over
time (‘High-High’ hope trajectory) (Table 3). Multinomial logistic regression revealed that T0
perceived susceptibility, comorbidity, having a medical or science occupation and T1 general anxiety
and depression significantly predicted hope trajectories, accounting for 56.1% of variability (Cox and
Snell R2) (Tables 2 & S4, Figure 2).
Compared with the ‘High-High’ hope trajectory, both the ‘High-Low’ (Odds Ratio, OR=1.05)
and the ‘Low-Low’ (OR=1.04) groups reported higher perceived susceptibility to cancer progression.
In addition, the ‘High-Low’ group had higher comorbidity compared to the ‘High-High’ (OR=1.98)
and ‘Low-High’ (OR=2.24) groups. Compared with the ‘High-High’ group, those in the ‘Low-High’
(OR=48.44) and ‘Low-Low’ (OR=10.61) groups were more likely to have a medical or science
occupation. Compared to the ‘High-High’ group, participants in the ‘High-Low’ (OR=1.61), ‘Low-High’
(OR=1.90) and ‘Low-Low’ (OR=1.81) groups had higher general anxiety scores, and participants in the
‘Low-Low’ (OR=1.40) groups reported higher depression. Compared to the ‘High-High’ group, the
‘High-Low’ (OR=0.26) and the ‘Low-Low’ (OR=0.04) groups had fewer radiotherapies in the past.
Compared to the ‘Low-High’ group, the ‘High-High’ (OR=2.93) and ‘High-Low’ (OR=3.52) groups had
higher number of surgeries in the past. The ‘High-High’, ‘High-Low’ and ‘Low-Low’ (OR=.98 for all
three) groups had shorter disease duration compared to the ‘Low-High’ group.
General anxiety
General anxiety decreased over time (Table 2). Multiple regression analyses revealed that
when controlling for T1 general anxiety, higher T2 general anxiety was predicted by gender, urban
versus rural status (ARIA), medical/science occupation, family history, lower comorbidity, lower T2
hope, and higher T2 general depression and T2 CGP-specific anxiety (p<.001, adj. R2=.71; Table S3).
Predictors of longitudinal anxiety. Most participants (55.6%) had low general anxiety over
time (‘Low-Low’ HADS-A trajectory) (Table 3). Several independent variables predicted general
anxiety trajectories accounting for 59.4% of variation in trajectory status (Tables 2 & S4, Figure 2).
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Compared with the ‘Low-Low’ general anxiety trajectory, the ‘High-High’ (OR=1.14), ‘High-Low’
(OR=1.12) and ‘Low-High’ (OR=1.15) groups had higher CGP-specific anxiety, whereas the ‘HighHigh’ (OR=.68) and ‘High-Low’ (OR=.77) groups reported lower hope. Compared to the ‘Low-High’
group, the ‘High-High’, ‘High-Low’ and ‘Low-Low’ groups were older (OR=1.17, OR=1.17, OR=1.19,
respectively), had lower comorbidity (OR=.20, OR=.23, OR=.36, respectively) and were more likely to
live in a major city (OR=101.67, OR=42.64, OR=69.41, respectively). The ‘High-High’ (OR=1.96) group
reported higher depression compared to the ‘Low-High’ group. The ‘High-Low’ (OR=.52) and ‘LowLow’ (OR=.55) groups had lower socioeconomic status compared to the ‘Low-High’ group.
Depression
General depression did not change over time (Table 2). Multiple regression analyses
showed that lower T2 hope and higher T2 general anxiety were significant predictors for higher
general depression at T2, when controlling for T1 general depression (p<.001, adj. R2=.77, Table S3).
Predictors of longitudinal depression. The majority of participants (71.4%) had low general
depression over time (‘Low-Low’ general depression trajectory group, Table 3). Multinomial logistic
regression analysis showed that socioeconomic status, having a family member diagnosed with
cancer, T1 hope and T1 general anxiety scores were significant predictors of general depression
trajectories accounting for 54.8% of variation in trajectory status (Tables 2 & S4, Figure 2). Compared
with the ‘Low-Low’ general depression trajectory, the ‘High-High’ (OR=.62) and ‘Low-High’ (OR=.84)
groups had lower levels of hope, whereas the ‘High-High’ (OR=3.20) and ‘High-Low’ groups
(OR=1.88) had higher general anxiety. Compared to the ‘Low-High’ group, both the ‘High-High’ and
the ‘High-Low’ groups had lower socioeconomic status (OR=.50, OR=.50, respectively) and higher
general anxiety (OR=3.42, OR=2.00, respectively). Compared to the ‘Low-Low’, the ‘High-Low’ group
had lower socioeconomic status. Compared to the ‘High-Low’ group, the ‘High-High’ group (OR=.14)
had a lower likelihood of having a relative with cancer.
CGP-specific anxiety
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CGP-specific anxiety decreased significantly over time (Table 2). In multiple regression
analyses, higher T2 CGP-specific anxiety was predicted by lower T0 perceived susceptibility and
higher T2 general anxiety (p<.001, adj. R2=.37), when controlling for T1 CGP-specific anxiety (Table
S3).
Predictors of longitudinal CGP-specific anxiety. Half of the participants (49.5%) had low
CGP-specific anxiety over time (‘Low-Low’ IES trajectory) (Tables 3 & S4, Figure 2). General anxiety,
not speaking English at home, ECOG and perceived susceptibility of cancer progression predicted
CGP-specific anxiety trajectories, accounting for 43.3% of variation in trajectory status (Table 3).
Compared with the ‘Low-Low’ group, the ‘High-High’ (OR=1.37) and ‘High-Low’ (OR=1.34) groups
reported higher general anxiety, whereas the ‘High-High’ (OR=7.11) group were more likely to not
speak English at home. Compared with the ‘High-Low’ group, the ‘High-High’ (OR=3.45) and the
‘Low-High’ (OR= 5.23) groups were more likely to have an ECOG score of ‘0’, whereas only the ‘HighHigh’ group reported lower perceived susceptibility of cancer progression (OR=.97).

Discussion
This study demonstrated that most participants had low levels of anxiety and depression
and high levels of hope after receipt of CGP results, all of which tended to decrease over time.
Psychological factors were strongly inter-related and predictive of each other, such that less hope
predicted higher anxiety and depression, and vice versa. Receipt of actionable results did not modify
psychological outcomes 2-3 months after receiving results. At T2, lower hope, and higher general
anxiety, depression and CGP-specific anxiety were associated with lower self-efficacy to cope with
results at T0. Participants with more positive attitudes to uncertainty experienced less hope and
higher CGP-specific anxiety, perhaps because their uncertainty (and the possibility of a more positive
outcome) was reduced by CGP results. Multiple demographic factors, worse health status and
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perceived susceptibility to cancer progression were independent predictors of one or more
psychological trajectories.
Our first hypothesis, that psychological outcomes would remain stable over time, was only
partially supported as only depression remained unchanged, whereas hope, general anxiety and
CGP-related anxiety decreased over time. The anxiety reduction may have been because participants
had more time to process the CGP outcome and/or may have received appropriate support and
guidance from healthcare professionals. Concurrently, having an advanced cancer with very limited
treatment options could explain the downward trend of hope over time. Hope is strongly related to
cancer stage and symptoms, as well as resilience and psychosocial factors (Mahendran et al., 2016;
Seiler, & Jenewein, 2019), can mediate the relationship between health status and psychological
stress (Rustøen, Cooper, & Miaskowski, 2010) and also be an effective coping strategy during the
cancer journey (Ebright, & Lyon, 2002). However, hopelessness can increase when no treatment
options have been identified, when multiple prior treatments have been ineffective (Kyriacou et al.,
2017) and when fear of cancer progression is high (Hamilton, Kruse, Holcomb, & Freche, 2018).
Interestingly, hope increased over time for participants with a medical or science occupation, who
possibly had increased education and understanding of genomics and therefore, better
management of expectations of their treatment.
Contrary to our second hypothesis, actionability of results did not affect psychological distress over
time, suggesting that actionable results and access to tailored treatment (if available) did not
provide sustained hope. Although outside of the scope of the current study, we suspect that with
time, participants’ expectations of tailored treatment may have reduced and other underlying
issues, such as worsening health or delays in receiving treatment, may have influenced participants’
stress and anxiety levels. Notably, CGP-specific anxiety, indicating worry about the CGP results, was
a significant predictor of general anxiety at T2; thus, CGP remained an important factor contributing
to psychological distress. It is difficult to compare these negative findings to other literature, as most
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studies of psychological responses to genomic testing have focused on germline testing or tumour
mutation profiling to predict recurrence or prognosis (Yanes et al., 2018). One study that examined
longitudinal responses of women with metastatic breast cancer before and after tumour NGS
genomic testing also found stable psychosocial scores (Adams et al., 2020). There was no correlation
found between the number of therapies recommended by the test and depression, anxiety, trust in
physician, self-efficacy, and genetic knowledge scores, further supporting the conclusion that results
do not impact psychological outcomes. Similarly, a meta-analysis of studies which included diverse
diseases (Frieser et al., 2018) concluded that return of genetic testing results for complex disease
does not strongly impact self-reported psychological function of at-risk individuals.
The third hypothesis was partially supported as younger age predicted higher anxiety at
follow-up (‘Low-High’ HADS-A trajectory); worse ECOG predicted lower CGP-specific anxiety (‘HighLow’ IES); and more comorbidities predicted lower hope (‘High-Low’ HHI) and increased anxiety
(‘Low-High’ HADS-A). Younger age has been found in a number of studies to predict greater distress
in cancer patients, perhaps because they feel more robbed of a longer life (Mystakidou et al., 2009).
Having more comorbidities often indicates poorer health, which can lead to loss of hope and higher
psychological distress as a result of progressive illness.
Interestingly, even those with better functional performance reported high CGP-specific
anxiety at follow up (‘High-High’ and ‘Low-High’ IES trajectories). Advanced cancer patients can
experience anxiety due to fear of cancer progression and uncertainty about illness prognosis
(Hamilton et al., 2018), despite their current level of well-being and physical health being relatively
good. This is important for healthcare professionals to consider; monitoring of, and responsiveness
to, distress should occur early in the advanced cancer trajectory and not be delayed until physical
decline is apparent.
Our final hypothesis was partially supported as higher self-efficacy at baseline was
associated with higher hope and lower general anxiety and depression and CGP-specific anxiety at
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T2 follow up, while more positive attitudes to uncertainty, lower perceived susceptibility to cancer
progression and higher perceived importance of CGP were associated with higher CGP-specific
anxiety. However, in multinomial regression analyses only lower perceived susceptibility to cancer
progression remained significant in predicting higher hope at follow up (‘High-High’ HHI). These
results suggest that psychological factors such as resilience, self-efficacy in coping and less perceived
susceptibility to cancer progression are protective against psychological distress, supporting earlier
findings (Hamilton et al., 2018). Overall, hope, general anxiety and depression, and CGP-specific
anxiety were strongly interrelated, and this resilience supported outcomes at T2, which
complements previous findings (Seiler, & Jenewein, 2019; Solano et al., 2016). Thus, these
potentially modifiable psychological factors could be a useful focus of further intervention studies to
generate greater resilience.
Notably, high perceived susceptibility also predicted higher CGP-specific anxiety (‘High-High’
IES), perhaps because these individuals were placing more hope on CGP to avoid the cancer
progression they anticipated. Discussion of future actions at the time of testing should CGP not
result in actionable findings might also help to alleviate this anxiety.
Overall, our findings provide some support for the Transactional Model of Stress and Coping
(Lazarus, & Folkman, 1984), providing further evidence that illness interpretations (perceived
susceptibility) and self-efficacy are important moderators of emotional distress. Uncertainty also
played a role as predicted by the Uncertainty in Illness model, although in a different direction to
that hypothesised, underlining the complex interactions between uncertainty and hope.

Clinical implications
Our results suggest that many individuals remain resilient and avoid significant psychological
morbidity, even as they grapple with advanced disease and encroaching death. However, some
patients do experience significant anxiety and depression and loss of hope and would benefit from
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appropriate interventions throughout their advanced cancer journey, particularly those with risk
factors such as younger age and more comorbidities. Preparing patients for different outcomes of
CGP would also help them gather resources to cope with results when they come.
Our current findings apply to a population with few conventional treatment options in the
terminal phase of therapy. As the relevance of CGP advances for all lines of cancer therapy, its use
will increasingly occur at earlier stages of the cancer journey.

Limitations of this study include that our sample were better functioning and had higher
self-efficacy than the MoST sample from which they were recruited. Psychological outcomes were
not collected at T0, which could have further added to our understanding how trajectories change
over time. Furthermore, there was a significant decrease in the proportion of participants who
completed T2; this is unsurprising as participants had advanced cancer and many became too ill to
respond or died. In addition, the unknown losses at T2 could have been due to an oncologist not
returning results if they felt they would not be informative or useful, or participants did not wish to
complete the questionnaire. In combination, these sample characteristics may have led to a positive
bias in results, with sicker, less resilient patients less well represented in the analysis leading to the
remaining sample having better health than the entire sample; thus, our results are not
generalisable to people who are sicker. Concurrently, patients who are sicker may not benefit as
much from the actionable results and treatment provided. This study included a limited number of
disease specific variables and the inclusion of additional clinical variables (e.g., treatment duration,
current cancer stage and stage at discovery/diagnosis, list of comorbidities) as well as health-related
quality of life would have been useful and might have improved our explanatory power. Only up to a
quarter of participants scored within the sub-clinical range of anxiety and depression at T1 and T2,
indicating that the studied population was relatively well adjusted and possibly had higher levels of
hope, which could limit the power for analyses.
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Overall, we found that many participants with advanced types of cancer maintained some
hope for comprehensive genomic profiling; however, receiving actionable result did not alter hope,
anxiety or depression after a few months of receiving results. This study furthers our understanding
of the predictors of psychological outcomes in the context of a lethal disease where there are only
limited treatment options available. By determining the frequency and severity of hopelessness,
anxiety and depression in this population, a well-designed intervention can be trialled that would
best address patients’ well-being.
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Table 1. Descriptive statistics for participants’ sociodemographic and disease variables
Total MoST sample
(n=1449)

Treatment
Treatment via MoST
Treatment via other
pathway
No actionable variant
NA
Gender
Female
Male
Education†
Up to high school (some
or all)
Vocational
Undergraduate
university
Postgraduate university
Marital status
Single, divorced, never
married, separated,
widowed
Married
Not stated
Has biological children
Not speaking English at
home, yes
Medical/science
occupation, yes
ARIA
Major city
Inner regional
Outer regional/ remote
Incidence
Common
Less common
Rare
Cancer diagnosis
Bone and soft tissue
Colon and/or rectum
Brain
Pancreas

Participants with T1 &
T2 psychological
outcomes (n=374)
N (%)

312 (21.5)
479 (33.1)

105 (27.9)
142 (37.8)

474 (32.7)
184 (12.7)

129 (34.3)
0

746 (51.5)
703 (48.5)

X2 (df)
76.80 (3)

p-value
.000

3.01 (1)

.083

3.96 (4)

.411

.34 (2)

.845

209 (55.6)
167 (44.4)

560 (38.6)

138 (36.7)

275 (19.0)
359 (24.8)

69 (18.4)
102 (27.1)

232 (16.0)

65 (17.3)

320 (22.1)

83 (22.1)

1100 (75.9)
26 (1.8)
1111 (76.7)
317 (21.9)

285 (75.8)
8 (2.1)
301 (80.1)
55 (14.6)

3.02 (1)
14.23 (1)

.082
.000

99 (6.8)

25 (6.6)

.02 (1)

.895

2.55 (2)

.279

2.68 (2)

.262

10.56 (10)

.393

1057 (72.9)
253 (17.5)
139 (9.6)

263 (69.6)
76 (20.2)
37 (9.8)

265 (18.3)
194 (13.4)
990 (68.3)

66 (17.6)
42 (11.2)
268 (71.3)

338 (23.3)
256 (17.7)
155 (10.7)
133 (9.2)

98 (26.2)
58 (15.5)
40 (10.7)
28 (7.5)
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Gynaecologic
Genitourinary
Breast
Unknown primary
Head and neck
Lung
Other
Treatments attempted
Surgery
0
1-3
4-11
Radiotherapy
0
1-3
4-6
Systemic
0
1-3
4-16
Multiple primary cancers,
yes†
ECOG score†
0
1
2
3
Comorbidity Index†
0
1
2
3
4-9
Family member
diagnosed with cancer,
yes

98 (6.8)
96 (6.6)
75 (5.2)
63 (4.3)
55 (3.8)
50 (3.5)
130 (9.0)

37 (9.9)
25 (6.7)
20 (5.3)
13 (3.5)
19 (5.1)
9 (2.4)
27 (7.2)

250 (17.3)
1113 (76.8)
86 (5.9)

185 (49.5)
185 (49.5)
4 (1.0)

136 (9.4)
995 (68.7)
318 (21.9)
111 (7.7)

43 (11.5)
251 (67.1)
80 (21.4)
62 (16.5)

724 (50.0)
649 (44.8)
61 (4.2)
4 (.3)

233 (62.0)
133 (35.4)
8 (2.1)
0
125 (33.2)
70 (18.6)
93 (24.7)
31 (8.2)
35 (9.3)
202 (53.7)

Mean (SD); range
Age, years
Socioeconomic status
Time since diagnosis
(months)
T0 self-efficacy
T0 knowledge

55.3 (14.32); 18-89
6.8 (2.85); 1.0010.00
49.9 (69.20); 0504.00
4.3 (.69); 1.00-5.00
43.1 (20.49); 0-100

.036

1.56 (1)

.459

1.50 (2)

.473

1.22 (1)

.269

29.86 (2)

.000

6.74 (4)

.150

3.31 (1)

.069

44 (11.8)
307 (82.1)
23 (6.1)

673 (46.4)
765 (52.8)
11 (0.8)

501 (34.6)
284 (19.6)
294 (20.3)
147 (10.1)
129 (8.9)
720 (49.7)

6.64 (2)

56.3 (13.53); 18-89
6.9 (2.81); 1.00-10.00
49.4 (68.87); 0.40504.00
4.4 (.63); 1.00-5.00
42.8 (20.07); 0-75

Mean
difference
(t-test)
1.07
.12

p-value
.193
.517

-.51

.907

.12
-.28

.003
.836
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T0 attitudes to
uncertainty
T0 perceived
susceptibility
T0 perceived importance
of CGP

4.4 (.55); 1.50-5.00

4.4 (.54); 1.50-5.00

.06

.114

67.3 (26.36); 0-100

68.3 (25.96); 0-100

1.03

.541

4.71 (.60); 1.00-5.00

4.74 (.58); 1.50-5.00

.03

.336

Abbreviations: ARIA – Accessibility and Remoteness Index of Australia; CGP – comprehensive genomic profiling; ; SD – standard deviation.
Notes: † - missing data.
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Table 2. Descriptive statistics for participants’ psychological outcome variables at T1 and T2
Psychological outcomes
cut-off scores low / high
T1 HHI (<35 / >36)
T2 HHI (<35 / >36)
T1 HADS-A (<7 / >8)
T2 HADS-A (<7 / >8)
T1 HADS-D (<7 / >8)
T2 HADS-D (<7 / >8)
T1 IES (<8 / >9)
T2 IES (<8 / >9)

Sample n
T1 HHI (343)
T2 HHI (343)
T1 HADS-A (374
T2 HADS-A (374)
T1 HADS-D (374)
T2 HADS-D (374)
T1 IES (374)
T2 IES (374)

Participants with T1 & T2 psychological
outcomes (n=374)
N (%)
167 (33.1) / 337 (66.9)
169 (31.4) / 370 (68.6)
338 (60.5) / 221 (39.5)
357 (66.0) / 184 (34.0)
425 (76.0) / 134 (24.0)
428 (79.1) / 113 (20.9)
328 (58.6) / 232 (41.4)
349 (64.9) / 189 (35.1)

Mean (SD); range
38.81 (5.52); 20-48
38.26 (5.31); 20-48
6.64 (4.18); 0-20
5.76 (4.15); 0-20
4.58 (3.69); 0-18
4.51 (3.59); 0-18
10.97 (13.23); 0-55
7.97 (11.89); 0-59
Participants with T1 Participants lost to
& T2 psychological follow-up at T1 or T2
outcomes

Main pairwise
difference
between T1 & T2
(SD)

p-value

.55 (4.01)

.011

.88 (2.95)

.000

.08 (3.17)

.648

3.00 (12.20)

.000

p-value

.017
.673
.048
.044
.000
.314
.310
.013

Sample n (lost to followup / T1-T2 psychological
outcomes completed)

Mean (SD); range

Mean (SD); range

Main
independent
samples
difference
between
remained & lost
to follow-up
sample (SE)

T1 HHI (161/343)
T2 HHI (196/343)
T1 HADS-A (185/374)
T2 HADS-A (167/374)
T1 HADS-D (185/374)
T2 HADS-D (167/374)
T1 IES (186/374)
T2 IES (164/374)

38.81 (5.52); 20-48
38.26 (5.31); 20-48
6.64 (4.18); 0-20
5.76 (4.15); 0-20
4.58 (3.69); 0-18
4.51 (3.59); 0-18
10.97 (13.23); 0-55
7.97 (11.89); 0-59

37.50 (6.18); 13-48
38.46 (5.23); 21-48
7.42 (4.68); 0-20
6.56 (4.35); 0-18
5.98 (4.23); 0-21
4.84 (3.66); 0-15
12.25 (15.34); 0-58
11.04 (13.69); 0-57

1.32 (0.55)
-.20 (0.47)
-.78 (0.39)
-.79 (0.39)
-1.40 (0.35)
-.34 (0.34)
-1.27 (1.25)
-3.07 (1.23)

Abbreviations: HADS – Hospital Anxiety and Depression Scale (Anxiety or Depression sub-scale); HHI – Herth Hope Index; IES – Impact of
Events Scale; SE – standard error.
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Table 3. Participant distribution in trajectories and multinomial logistic regression of predictors
of hope (HHI), anxiety (HADS-A), depression (HADS-D) and CGP-specific anxiety (IES) (n=374)

HHI

HADS-A HADS-D
N (%)

IES

Trajectories
High-High (n=342)
High-Low (n=374)
Low-High (n=374)
Low-Low (n=374)

Continuous variables
Age
Socioeconomic status
Comorbidity Index
Time since first cancer diagnosis (months)
Previous surgeries
Previous radiotherapies
Previous systemic treatments
T0 Perceived susceptibility
T0 Perceived importance of CGP
T0 Knowledge
T0 Self-efficacy
T0 Attitude towards uncertainty
T1 HHI
T1 HADS-Anxiety
T1 HADS-Depression
T1 IES
Categorical variables
Treatment recommendation (no actionable/
actionable via MoST/ actionable via other
pathway/ NA)
Gender (female/male)
Education (up to high school/
vocational/undergraduate/ postgraduate)
Parental status (has children/ no children)
Speaking non-English at home (yes/no)
Medical/science occupation (yes/no)
ARIA (major city/inner regional/outer
regional)
Incidence (common/ less common/ rare)
Multiple primary cancers (yes/no)
ECOG score (0/1+)
Family member diagnosed with cancer
(yes/no)

198 (57.9)
41 (12.0)
32 (9.4)
71 (20.8)

92 (24.6)
48 (12.8)
26 (7.0)
208 (55.6)

40 (10.7)
33 (8.8)
34 (9.1)
267 (71.4)

85 (22.7)
67 (17.9)
37 (9.9)
185 (49.5)

Likelihood Ratio test p-values
HHI
HADS-A
HADS-D
IES
.391
.013
.111
.350
.294
.015
.003
.230
.009
.004
.432
.467
.009
.015
.731
.339
.037
.355
.091
.071
.000
.061
.008
.068
.324
.370
.004
.512
.000
.153
.006
.015
.099
.448
.699
.324
.232
.399
.063
.459
.496
.901
.040
.693
.046
.657
.017
.143
NA
.000
.001
.493
.000
NA
.000
.000
.005
.010
NA
.745
.015
.000
.242
NA
.805

.202

.751

.402

.154
.682

.722
.347

.095
.018

.176
.420

.867
.846
.010
.196

.345
.494
.146
.031

.015
.014
.093
.022

.696
.005
.165
.941

.047
.316
.286
.171

.853
.358
.030
.860

.764
.025
.078
.007

.625
.826
.013
.487

Abbreviations: ARIA – Accessibility and Remoteness Index of Australia; CGP – comprehensive genomic profiling; CI – confidence intervals;
ECOG – Eastern Cooperative Oncology Group; HADS – Hospital Anxiety and Depression Scale (Anxiety or Depression sub-scale); HHI –
Herth Hope Index; IES – Impact of Events Scale; SE – standard error.
Notes: P-values below the Bonferroni correction (< .00185) highlighted in bold.
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Figure 1. Participant flow in the study
Referred to MoST (n=1647)

Enrolment

Consented to participate (n=1537)

Completed T0 (n=1431)

Received result and sent T1 (n=1170)*

Incomplete/Excluded (n=106)
Unknown (n=70)
 Unable to speak sufficient English
(n=23)
 Too ill (n=9)
 Refused (n=4)

Not sent (n=367)
 No MTB report issued (n=133)
 Deceased before MTB (n=63)
Too ill (n=56)
 Unable to speak sufficient English
(n=17)
Refused (n=2)
Other (n=96)

Incomplete (n=601)
 Unknown (n=456)
 Too ill (n=89)
 Refused (n=22)
 Other (n=34)

Completed T1 (n=569)

Actionability
Actionable result (n=364)
via MoST study (n=154)
via other pathway (n=210)

Not sent (n=247)
 Deceased (n=233)
 Too ill (n=1)
 Refused (n=4)
 Unable to speak sufficient English
(n=2)
 Other (n=7)

Non-actionable result (n=205)

Did not decline T1, Sent T2 (n=971)**

Completed T2 (n=548)

Incomplete (n=423)
 Unknown (n=343)
 Too ill (n=51)
 Refused (n=15)
 Unable to speak sufficient English
(n=6)
 Other (n=8)

Non-actionable result (n=201)

Actionable result (n=347)
 via MoST study (n=150)
 via other pathway (n=197)

Analysis
Analysed (n=244)
 Excluded as either T1 or T2 missing (n=103)

Analysed (n=130)
 Excluded as either T1 or T2 missing (n=71)

Abbreviations. MoST – Molecular Screening and Therapeutics Programme; MTB – molecular tumor board.
Notes. *T1 sent to everyone; not just those who completed T0.
**T2 sent to those who had an MTB issued, were not deceased, did not decline completing T1.
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Figure 2. Multinomial logistic regression analyses of linear predictors of hope (HHI, n = 342), anxiety (HADS-A), depression (HADS-D) and CGP-specific
anxiety (IES) (n=374)

HHI

T0 perceived susceptibility

Comorbidity Index

.002
.000
.002

HHI

T1 HADS-A

.016

T1 HADS-D

.002

.014

30
PSYCHOLOGICAL OUTCOMES AFTER GENOMIC PROFILING

HADSA

Age

Socioeconomic status

.008
.018

.013
.020

HADSA

T1 HHI

Comorbidity Index

.007

.042
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HADSA

T1 HADS-D

T1 IES

.013

.002

.033

HADSD

Socioeconomic status

T1 HHI
.013

.025

.002
.017
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HADSD

T1 HADS-A

.001
.001

IES

T0 perceived susceptibility

T1 HADS-A

.017

.002
.008

Abbreviations: CGP – comprehensive genomic profiling; HADS – Hospital Anxiety and Depression Scale (Anxiety or Depression sub-scale); HHI – Herth Hope Index; IES – Impact of Events Scale.

